Dose regimen for administration of LAG-3/PD-L1 bispecific antibodies

A technology of PD-L1 and LAG-3, applied in the direction of antibodies, antibody medical components, specific peptides, etc., can solve the problems that LAG-3/PD-L1 antibodies have not yet been obtained

Pending Publication Date: 2022-03-18
F STAR THERAPEUTICS LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] No data are available to date on the properties of LAG-3/PD-L1 antibodies...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dose regimen for administration of LAG-3/PD-L1 bispecific antibodies
  • Dose regimen for administration of LAG-3/PD-L1 bispecific antibodies
  • Dose regimen for administration of LAG-3/PD-L1 bispecific antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0218] Example 1: First in human (FIH) dose justification and dose escalation strategy for FS118 slightly

[0219] FS118 is a bispecific antibody molecule that simultaneously targets two immune checkpoint proteins, LAG-3 and PD-L1. FS118 has been shown to differ from monospecific immune checkpoint inhibitors, such as anti-PD-L1 antibodies, in a number of important ways. These differences require detailed analysis to determine the appropriate dose for Phase I studies of FS118 in human patients. Specifically, FS118 was tested in in vitro and in vivo studies to determine the optimal starting dose and dose escalation strategy for a phase I human study designed to determine the efficacy of FS118 in patients with previously PD-containing Safety, tolerability, pharmacokinetics and activity in patients with advanced malignancies who have progressed on or after 1 / PD-L1 therapy (see Example 2 below).

[0220] 1.1 FS118 and mLAG-3 / PD-L1: Overview of nonclinical studies

[0221] ...

Embodiment 2

[0330] Example 2: LAG-3 / PD-L1 bispecific antibody FS118 on or during prior PD-1 / PD-L1 containing therapy Phase I, open-label, safety, tolerability, pharmacokinetics, and activity in patients with advanced malignancies after progression Dose Escalation and Cohort Expansion First-in-Human Study

[0331] 2.1 Study Design and Parameters

[0332]Studies were conducted in adult patients diagnosed with advanced tumors to characterize the safety, tolerability, pharmacokinetics (PK) and activity of FS118. This phase I, multicenter, open-label, multiple-dose, first-in-human study was initiated with an accelerated titration design (over which a single patient cohort was evaluated) followed by a 3+3 ascending dose escalation design. The study was designed to systematically assess the safety and tolerability, maximum tolerated dose (MTD) and / or phase II recommended dose (RP2D) of FS118 in patients with confirmed advanced tumors. RP2D is defined as the maximum biologically effectiv...

Embodiment 3

[0490] Example 3: Selection of those more likely to respond to FS118 based on resistance to prior anti-PD-1 or anti-PD-L1 therapy patient

[0491] 3.1 Background

[0492] All patients included in the ongoing FS118 trial progressed on or after PD-1 / PD-L1-containing therapy.

[0493] Initial results (August 2019) demonstrated that FS118 was able to stabilize disease in some patients with a disease control rate (DCR) of 34.4% (see Example 2.3.1), rising to 47.2% as of April 2020 (see Implementation Example 2.4.1). The inventors hypothesized that FS118 could provide benefit to these patients due to the combination of a LAG-3 inhibitor with a PD-L1 inhibitor (dual checkpoint inhibitor) or by a PD-L1 and LAG-3 bispecific Additional benefits provided by targeting novel biology (WO2017220569A1). Patients are not expected to realize clinical benefit on retreatment with anti-PD-1 or anti-PD-L1-containing regimens alone (Fujita et al., Anticancer Res. (2019); Fujita et al., Thor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present application relates to dosage regimens for the administration of antibody molecules that bind programmed death-ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients.

Description

technical field [0001] The present invention relates to dosage regimens for administration of antibody molecules that bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). dosage regimes) and their medical use in the treatment of cancer in human patients. The present invention also provides prognostic thresholds for predicting the likelihood that a human patient will respond to an antibody. Background technique [0002] Cancer is a complex disease for which there are still significant unmet needs. In recent years, the interaction between the host immune system and the tumor has become an area of ​​intense non-clinical and clinical assessment. Tumor infiltrating lymphocytes (TILs) have the ability to control tumor cell growth, and emerging clinical evidence suggests that patients with increased TILs have a favorable prognosis. Overall, T cells play a major role in immune defense against cancer and regulation of T cell activation is mediated by...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/46A61K39/395A61P35/00A61P35/02
CPCC07K16/2803C07K16/2827A61P35/00A61P35/02C07K2317/31C07K2317/76A61K2039/545A61K2039/505A61K2039/54C07K2317/56C07K2317/90
Inventor 米歇尔·莫罗菲奥纳·杰马斯切夫斯基丹尼尔·格利登梁健美克里斯蒂安·格拉迪纳鲁克里斯托弗·谢泼德约瑟芬-比特·霍尔茨露易丝·凯塔利尔
Owner F STAR THERAPEUTICS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap